Cargando…

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

BACKGROUND: Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to compare the effects of zoledronic acid versus clodronic acid in newly diagnosed patients with multiple m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, Gareth J, Child, J Anthony, Gregory, Walter M, Szubert, Alex J, Cocks, Kim, Bell, Sue E, Navarro-Coy, Nuria, Drayson, Mark T, Owen, Roger G, Feyler, Sylvia, Ashcroft, A John, Ross, Fiona M, Byrne, Jennifer, Roddie, Huw, Rudin, Claudius, Cook, Gordon, Jackson, Graham H, Wu, Ping, Davies, Faith E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148431/ https://www.ncbi.nlm.nih.gov/pubmed/21771568 http://dx.doi.org/10.1016/S1470-2045(11)70157-7

Ejemplares similares

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2010)

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
por: Boyd, Kevin D, et al.
Publicado: (2011)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

The treatment of multiple myeloma--an important MRC trial.
por: Johnson, P. W., et al.
Publicado: (1994)

Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo
por: Opperman, Khatora S., et al.
Publicado: (2019)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study
por: Spencer, Andrew, et al.
Publicado: (2008)

Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report
por: Noriega Aldave, Adrian P, et al.
Publicado: (2014)

The stunning clodronate
por: Mass, Elvira
Publicado: (2023)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Treatment of malignant hypercalcaemia with clodronate.
por: Percival, R. C., et al.
Publicado: (1985)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
por: Carmichael, Jonathan, et al.
Publicado: (2023)

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
por: Raje, N, et al.
Publicado: (2016)

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
por: Richardson, Paul G, et al.
Publicado: (2012)

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
por: Boyle, Eileen M, et al.
Publicado: (2015)

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
por: Bruzzese, F, et al.
Publicado: (2013)

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology
por: Fusco, Vittorio, et al.
Publicado: (2018)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

Molecular profiling in myeloma
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
por: Raje, Noopur, et al.
Publicado: (2019)

Indirect osteoblast differentiation by liposomal clodronate
por: Okada, Emi, et al.
Publicado: (2017)

Dissecting racial disparities in multiple myeloma—clues from differential immunoglobulin levels
por: Bunce, C. M., et al.
Publicado: (2020)

Zoledronic acid in the management of metastatic bone disease
por: Polascik, Thomas J, et al.
Publicado: (2008)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent
por: Feyler, Sylvia, et al.
Publicado: (2012)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Zoledronic acid for neonatal subcutaneous fat necrosis
por: Di Bari, Jeremy A., et al.
Publicado: (2017)

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
por: Jiang, Lianghai, et al.
Publicado: (2021)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

The anti-tumour effects of zoledronic acid
por: Zekri, Jamal, et al.
Publicado: (2014)

Zoledronic Acid–Induced Interface Dermatitis
por: Succaria, Farah, et al.
Publicado: (2015)

Meta-analysis of clodronate and breast cancer survival
por: Ha, T C, et al.
Publicado: (2007)

Clodronate as a Therapeutic Strategy against Osteoarthritis
por: Valenti, Maria Teresa, et al.
Publicado: (2017)

The Rationale for the Intra-Articular Administration of Clodronate in Osteoarthritis
por: Moretti, Antimo, et al.
Publicado: (2021)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pr2npbn7tabf0h7lh9bv4vl72s